Trial Profile
A Single-arm, Open-label, Multicenter, Non-interventional Study to Assess Bevacizumab (Avastin) in Relapsed Glioblastoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Roche
- 26 Feb 2018 Status changed from not yet recruiting to completed.
- 18 Mar 2013 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.
- 15 Aug 2012 Actual initiation date changed from 1 Jun 201 2 to 1 Dec 2012 as reported by ClinicalTrials.gov.